Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 14/20 | 0.75 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.61 |
| ▸ | CDK9 | P50750 | 5/20 | 0.61 |
| ▸ | CCNH | P51946 | 5/20 | 0.61 |
| ▸ | CCNK | O75909 | 4/20 | 0.61 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.61 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.61 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.45 |
| ▸ | JUN | P05412 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665176 | 1.00 | CDK7 (0.75) | CDK7CCNT1CDK9CCNHCCNK | |
| Hydrochloric Acid SCHEMBL18047324 | 0.99 | CDK7 (0.74) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL18047328 | 0.91 | CDK7 (0.65) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL28882404 | 0.90 | CDK7 (0.62) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL18047310 | 0.88 | CDK7 (0.63) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL16665180 | 0.88 | CDK7 (0.63) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL19605659 | 0.86 | CDK7 (0.60) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL17696325 | 0.86 | CDK7 (0.60) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL17688401 | 0.86 | CDK7 (0.57) | CDK7CCNT1CDK9CCNHCCNK | |
| SCHEMBL22778392 | 0.86 | CDK7 (1.00) | CDK7CCNT1CDK9CCNHCCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | PARAZA PHARMA, INC. (CA) | 2019-01-31 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CCNT1 45/4885CDK9 16/4885 |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CCNT1 45/4885CDK9 16/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CCNT1 45/4885CDK9 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.